Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
BUSINESS
BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
Bristol Myers Squibb is poised to counter a wave of patent cliffs in Japan with four new products and label expansions for Opdivo (nivolumab) to double its sales in the country over the next decade, the company’s local president Steve…
To read the full story
Related Article
- Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
- BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
BUSINESS
- Daiichi Sankyo Puts Up 600 Billion Yen to Bolster ADC Supply Regime
December 18, 2024
- Takeda, Tohoku University Form Strategic Alliance to Expedite Drug R&D
December 18, 2024
- Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- Kyorin Licenses Novel OSA Treatment from Bayer
December 17, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…